GlassScriptPhysician profile
Angela Y Rice
NPI 1134231822
$5,060.55
in general payments reported to CMS, 2019-2025
30 companies · $974 in 2025
The $974 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $156 · 2021: $50.55 · 2022: $739 · 2023: $1,319 · 2024: $1,241 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,521 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.99 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $931.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $827.13 | 2022-2025 | |
| Lilly USA, LLC | $546.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $511.31 | 2019-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $321.04 | 2022-2025 | Verquvo, Steglatro, Zerbaxa |
| Glaxosmithkline, LLC. | $288.60 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.25 | 2023-2025 | Xifaxan, Relistor |
| Medtronic, INC. | $165.49 | 2021-2024 | Endurant Iis, Minimed 780g, Minimed 770g |
| Ardelyx, INC. | $155.73 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $135.56 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.21 | 2019-2025 | Jardiance |
| Amgen INC. | $102.55 | 2019-2022 | |
| Dexcom, INC. | $101.17 | 2022-2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $74.92 | 2019 | |
| Amarin Pharma, INC. | $71.55 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.66 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $64.48 | 2024-2025 | Voquezna |
| Allergan, INC. | $51.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.83 | 2019-2023 | |
| Astellas Pharma US INC | $44.12 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $43.30 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $36.29 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $30.02 | 2022-2023 | |
| Radius Health, INC. | $29.29 | 2019-2025 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $28.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.27 | 2023 | Gvoke Hypopen |
| Verona Pharma, INC. | $22.14 | 2025 | Ohtuvayre |
| Kyowa Kirin, INC. | $20.95 | 2025 | |
| Exact Sciences Corporation | $15.34 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.